Insulin resistance, usually defined as an impaired ability of insulin to maintain normal glucose metabolism and initially manifested as higher levels of circulating insulin, is positively associated with adi posity and is a key mediator of the link between obesity and its adverse impact on metabolic and cardiovascular disease [1] [2] [3] [4] [5] [6] [7] [8] . Given the cur rent global epidemic of metabolic disease, there is an urgent need for improved understanding of the mechanisms that link overnutrition to insulin resistance in the general population [7] [8] [9] [10] .
Among individuals stratified on the basis of overall adipos ity, there is considerable variation in the extent of adverse meta bolic sequelae 11 , demonstrating the importance of other factors in the etiology of insulin resistance and its complications. Indeed, although insulin resistance often coexists with obesity, severe forms of insulin resistance develop without obesity or in association Insulin resistance is a key mediator of obesity-related cardiometabolic disease, yet the mechanisms underlying this link remain obscure. Using an integrative genomic approach, we identify 53 genomic regions associated with insulin resistance phenotypes (higher fasting insulin levels adjusted for BMI, lower HDL cholesterol levels and higher triglyceride levels) and provide evidence that their link with higher cardiometabolic risk is underpinned by an association with lower adipose mass in peripheral compartments. Using these 53 loci, we show a polygenic contribution to familial partial lipodystrophy type 1, a severe form of insulin resistance, and highlight shared molecular mechanisms in common/mild and rare/severe insulin resistance. Population-level genetic analyses combined with experiments in cellular models implicate CCDC92, DNAH10 and L3MBTL3 as previously unrecognized molecules influencing adipocyte differentiation. Our findings support the notion that limited storage capacity of peripheral adipose tissue is an important etiological component in insulin-resistant cardiometabolic disease and highlight genes and mechanisms underpinning this link. 1 25, 26 . However, the relevance of this model to the general human population remains uncertain.
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Some initial human genetic insights into more prevalent forms of insulin resistance are available. Genomewide studies of 'gold standard' measures of insulin resistance have been limited by sample size 27 , but multiple genomic loci have been associated with fasting insulin levels, a widely measured marker of insulin resistance 28, 29 . A subset of these loci were associated with higher triglyceride and lower HDL cholesterol levels 28 , which are hallmarks of insulin resist ance 13, 30 . These loci were later validated for their association with insulin resistance 31 , suggesting that combined association with this triad of phenotypes could help identify specific genetic determinants of insulin resistance.
Given the availability of largescale genomewide association data on lipid traits and fasting insulin levels 28,29,32 , we undertook an inte grative genomic approach to characterize genetic and molecular mech anisms underpinning insulin resistance at a given level of adiposity and the role of insulin resistance in cardiometabolic disease in the general population.
RESULTS
Associations with insulin resistance phenotypes at 53 independent genomic regions
We combined genomewide association results for fasting insulin adjusted for body mass index (BMI) 22, 23 , HDL cholesterol and tri glyceride levels 32 from up to 188,577 individuals to identify loci associ ated with a phenotypic pattern indicative of insulin resistance (Online Methods, Supplementary Figs. 1 and 2, and Supplementary Table 1) . After aligning the association results of ~2.4 million SNPs to the insulinraising allele, 630 SNPs from 53 1Mb genomic regions were associated with higher fasting insulin, higher triglyceride and lower HDL cholesterol levels (P < 0.005 for each phenotype; expected prob ability of association under the null hypothesis, P = 3.1 × 10 −8 ; Online Methods and Supplementary Figs. 3 and 4) . These 53 genomic regions included 10 loci previously implicated in insulin resistance 31 and an additional 43 loci (Supplementary Table 2 ). A subset of 25 of the 53 loci had previously been associated with HDL cholesterol or triglyceride levels at genomewide significance 32 , whereas 28 had not (Supplementary Table 2 ). We first investigated the associations of these loci in a completely independent sample of 6,101 individuals and found that genetic risk scores comprising the 53 lead SNPs were strongly associated with higher fasting insulin, higher triglyceride and lower HDL cholesterol levels ( Supplementary Fig. 5 ). We next asked whether these variants were associated with goldstandard measures of insulin sensitivity. Having a greater number of risk alleles from the 53 SNP, 43SNP or 28SNP genetic score (all loci and excluding loci pre viously implicated in insulin resistance and lipid traits, respectively) was strongly associated with (i) lower insulin sensitivity as measured by euglycemic clamp or insulin suppression test in 2,764 individu als 27 (P value for the 53SNP genetic score = 4.3 × 10 −6 ; Table 1 ) and (ii) lower insulin sensitivity index in 4,769 individuals with a frequently sampled oral glucose tolerance test 33 (P value for the 53SNP genetic score = 7.3 × 10 −10 ; Table 1 ).
Genetic predisposition to insulin resistance via the 53 loci confers higher risk of cardiometabolic disease but lower levels of peripheral adiposity
We next investigated associations of the 53 genomic regions with a range of continuous metabolic traits and disease outcomes. In 45,836 cases and 230,358 controls, the 53SNP genetic score was associated with higher risk of type 2 diabetes (odds ratio (OR) per 1 s.d. of the genetic score (~4.5 alleles) = 1.12, 95% confidence interval (CI) = 1.11-1.14; P = 9.2 × 10 −61 ; Table 1 ). In studies with available individuallevel data, we saw no difference in associations across sex or BMI strata (Supplementary Table 3 ). Genetically predicted insulin resistance was also associated with higher risk of coronary heart disease ( Table 1 ). The associations with type 2 diabetes (OR = 1.10; P = 9.0 × 10 −32 ) and coronary heart disease (OR = 1.04; P = 9.7 × 10 −7 ) remained after removing 13 loci that were previously shown to be asso ciated with either of the two diseases at genomewide significance 34, 35 . Results are displayed for genetic scores comprising (i) the lead SNP at each of the 53 associated loci, (ii) the lead SNP at each of the 43 additional loci identified in this study after removing 10 loci previously implicated in insulin resistance, or (iii) the lead SNP at each of the 28 loci not previously associated with HDL cholesterol or triglyceride levels. β coefficients are in standardized units per 1 s.d. of the 53-SNP genetic score (4.5 alleles), and odds ratios are per 1 s.d. of the 53-SNP genetic score (4.5 alleles). Association with insulin sensitivity is from 2,764 participants of the GENESIS Consortium 27 , and association with insulin sensitivity index is from 4,769 participants of the MAGIC Consortium who underwent a frequently sampled oral glucose tolerance test (OGTT) 33 ; association with type 2 diabetes is from the InterAct, DIAGRAM and UK Biobank studies, and association with coronary heart disease is from the CARDIoGRAM and C4D consortia. n, number of participants; SE, standard error; CI, confidence interval.
a In GENESIS 27 , insulin sensitivity was measured by clamp or insulin suppression test using study-specific parameters (for example, glucose disposal or M value), which were then standardized before meta-analysis. b In MAGIC 33 , insulin sensitivity index (ISI) = 10,000/√(fasting plasma glucose (mg/dl) × fasting insulin × mean glucose during OGTT (mg/dl) × mean insulin during OGTT).
A r t i c l e s A r t i c l e s Association estimates were also consistent after removing the 25 loci previously associated with HDL cholesterol or triglyceride levels at genomewide significance ( Table 1) . We also observed an asso ciation with coronary heart disease in 5,369 cases of coronary heart disease and 106,969 controls from the UK Biobank study not previ ously included in genomewide discovery analyses of insulin or lipid traits (OR = 1.09; P = 5.3 × 10 −9 ). Individually, 30 of the 53 lead SNPs were associated with higher type 2 diabetes risk (P < 0.05; Supplementary Table 4) , including a new association at genome wide significance for rs718314 near ITPR2 (OR per allele = 1.06; P = 6.8 × 10 −9 ). We found an enrichment of loci associated with higher risk of both type 2 diabetes and coronary heart disease, including those encompassing the proximal insulin signaling INSR, IRS1 and PIK3R1 genes (11/53 loci associated with both diseases at P < 0.05; twotailed binomial probability of observing this proportion of loci by chance, P = 8.5 × 10 −22 ; Supplementary Table 5) . Although insulin resistance is often considered secondary to higher adiposity, at the 53 loci, we observed associations with lower body fat percentage, BMI and hip circumference ( Fig. 1a and Supplementary  Figs. 6 and 7) . The larger magnitude of association with measures of body fat rather than with glycemic phenotypes is consistent with a primary effect of many variants on adipose tissue mass ( Fig. 1a and Supplementary Figs. 6 and 7) .
In followup studies using dualenergy Xray absorptiometry (DEXA) measures in 12,848 individuals, we found that the most marked association of the genetic score was with lower levels of gynoid and leg fat mass (Fig. 1b) . Individuals in the highest quintile for the 53SNP genetic score had an average of 712 g less leg fat mass than individuals in the bottom quintile (Fig. 1c) , which accounted for the majority of the overall body fat association ( Supplementary  Fig. 8 ). The association with lower levels of leg fat was accompanied by a higher hazard of incident type 2 diabetes (Fig. 1c) . In 9,150 par ticipants from the EPICNorfolk cohort who gained weight during a median followup time of 3.7 years, carrying a greater number of the 53 risk alleles was inversely associated with change in hip circumfer ence, adjusted for the amount of weight gained (that is, individuals carrying more risk alleles were less likely to deposit extra mass in their gluteal region for a given increase in body mass; β in centimeters of hip circumference per 1 s.d. of genetic score = −0.07; P = 0.027; Supplementary Note). Overall, these association analyses suggest that individuals genetically predisposed to insulin resistance via the 53 loci have a relative inability to expand their peripheral fat compartment when challenged by a positive energy balance and that this incapacity results in higher cardiometabolic disease risk. We also found that the 53SNP genetic score was associated with higher levels of alanine ami notransferase and γglutamyltransferase (Supplementary Table 6 ), suggesting that the failure to store lipids in gluteofemoral adipose tissue may be accompanied by hepatic lipid deposition.
The 53SNP genetic score was associated with greater waist circum ference (Fig. 1a) but not with trunk adipose tissue (Fig. 1b) , indicating that the association between body fat distribution and cardiometa bolic disease was largely driven by the association with lower levels of peripheral adipose tissue ( Fig. 1 and Supplementary Figs. 
6-8).
Of the 53 lead SNPs, 17 were within 500 kb of a waist-hip ratio (WHR) associated SNP 36 (Supplementary Fig. 6 ). Consistent with DEXA analyses, the associations with WHR at this subset of overlapping loci were largely driven by an association with lower hip circumfer ence, rather than greater waist circumference ( Supplementary Fig. 6 and Supplementary Table 4) .
Our largescale metaanalyses allowed the investigation of indi vidual SNP associations with both adiposity and metabolic risk. At 8 of the 53 loci, the lead SNP was associated with lower total body fat percentage or hip circumference at genomewide significance (P < 5 × 10 −8 ), including a new association of the insulinraising G allele of rs4976033 near PIK3R1 with lower body fat percentage (P = 3.0 × 10 −9 ; Fig. 1d and Supplementary Fig. 9 ). Seven of the eight adipositylowering alleles at these loci were associated with a higher risk of type 2 diabetes (P < 0.05; Fig. 1d ).
Role of common variants in the genetic basis of a severe form of lipodystrophy
Given the strong association with insulin resistance but lower levels of peripheral adiposity, we hypothesized that the polygenic predisposi tion to insulin resistance imparted by the 53 loci might contribute to the pathogenesis of familial partial lipodystrophy type 1 (FPLD1). When compared to women from the populationbased Fenland study, women diagnosed with FPLD1 displayed markedly lower levels of leg fat mass for a given fat mass in the rest of the body (Fig. 2a) . Although the name of the condition implies Mendelian inheritance, using exome sequencing in nine FPLD1 cases, we did not identify likely candidate causal genes (Online Methods and Supplementary Table 7) . When compared with 5,296 unrelated women from the UKHLS study in a case-control analysis, 37 patients with FPLD1 had a higher burden of the 53 risk alleles (OR per 1 s.d. of genetic score in logistic regression analyses adjusted for age and the first ten A r t i c l e s A r t i c l e s genetic principal components = 1.70, 95% CI = 1.21-2.39; P = 0.0021, Fig. 2b ; P permutation = 0.0020, Online Methods). Also, the phenotypes observed in patients with FPLD1 in comparison to obese women from the Fenland study mirrored the association pattern of the 53SNP genetic score (Supplementary Table 8 ). Women with FPLD1 had a more severe leg fat phenotype than expected from the relation ship between the 53SNP score and leg fat mass in the Fenland study (Fig. 2c) , suggesting that additional genetic and environmental factors contribute to determining this extreme phenotype.
Prioritization of putative effector genes, cell types and tissues
We prioritized putative effector genes at the 53 loci by integrating data about physical proximity, expression quantitative trait locus (eQTL) mapping, functional annotation and previous knowledge on genes causing monogenic forms of insulin resistance (summarized in Supplementary Table 2; see also Supplementary Tables 9-11 for details). The putative effector genes included five with wellestab lished roles in proximal insulin signaling ( Fig. 3a and Supplementary Table 2 ). Other candidates included LPL, encoding the key lipolysis regulator lipoprotein lipase ( Fig. 3b and Supplementary Table 2 ).
The insulinlowering minor allele of rs1011685 (near LPL) is on the same haplotype (r 2 = 1) as a gainoffunction 37 , proteintruncating allele in LPL (p.Ser447*; rs328; minor allele frequency (MAF) = 9.9%). The p.Ser447* gainoffunction variant was recently reported to be associated with lower risk of coronary heart disease 38 , while an inde pendent lossoffunction missense variant of LPL 39 (p.Asp36Asn; rs1801177; MAF = 1.9%) was associated with higher risk 38 . Here we found that the p.Ser447* gainoffunction variant is associated with greater insulin sensitivity, lower fasting glucose, lower levels of liver markers and protection from type 2 diabetes (OR per allele = 0.93; P = 1.6 × 10 −5 ; Fig. 3b and Supplementary Fig. 10 ). Conversely, the p.Asp36Asn lossoffunction variant in LPL is associated with higher risk of type 2 diabetes (OR per allele = 1.11; P = 0.0086; Fig. 3b and Supplementary Fig. 10 ). Thus, recent findings of an allelic series of LPL variants implicating lipoprotein lipase as a putative therapeutic target in heart disease 38 are now complemented by a directionally consistent observation for type 2 diabetes, compatible with a role for impaired lipoproteinlipasemediated lipolysis in insulin resistance and type 2 diabetes. Of the 53 loci, 3 contained genes at which rare mutations have previously been implicated in severe monogenic forms of insu lin resistance (PPARG, PIK3R1 and INSR; Fig. 3c ), which is more than what is expected by chance given the prevalence of mono genic insulinresistanceassociated genes in the genome (observed percentage = 0.54% (3 of a total of 553 genes in the 53 loci), expected percentage = 0.064%; twotailed binomial P = 0.0056). The PIK3R1 gene encodes regulatory subunits of a critical kinase involved in proximal insulin signaling, and rare, lossoffunction mutations in this gene are associated with SHORT syndrome, a dysmorphic condi tion characterized by short stature, partial lipodystrophy and insulin resistance [40] [41] [42] [43] . Thus far, such mutations have been identified in few families worldwide, and data from the Exome Aggregation Consortium show this gene to have a decreased tolerance for missense variation (z = 2.42) and to be particularly intolerant of lossoffunction A r t i c l e s mutations (pLI = 1). Here we provide evidence that a common variant near PIK3R1, which accounts for almost half of all alleles in the general population (MAF = 49%), is associated with subtle effects on insulin resistance, lower body fat percentage, and higher risk of type 2 diabetes and coronary heart disease ( Supplementary Fig. 9 ). This association pattern partially overlaps with that reported for PIK3R1 mutations and SHORT syndrome (Supplementary Table 12 ). We also found that the common rs8101064[T] allele in INSR, encoding the insulin receptor, was associated with insulin resistance and higher risk of type 2 diabetes (OR per allele = 1.08; P = 0.020) but not with body fat percentage (P = 0.16), consistent with the fact that patients with heterozygous lossoffunction mutations in INSR are frequently insulin resistant but are not commonly lipodystrophic 13 .
We assessed the overlap of lead SNPs and their proxies (r 2 > 0.8) with functional regulatory annotations across 98 cell types from the NIH Epigenomics Roadmap (Online Methods) and, consistent with phenotypic associations, identified substantial overlap with enhancer elements active in adipose tissue (31 of 53 loci overlapped enhancer elements active in adipose tissue; observed percentage = 58.4% of loci, expected percentage = 30.1% of loci; binomial P = 2.1 × 10 −5 ; Fig. 3d and Online Methods). Furthermore, combined pathway analyses with integration of largescale gene expression data 44 implicated adipocytes as a likely effector cell type underlying the observed asso ciations (Fig. 3e) . In subcutaneous adipocyte eQTL data from 1,064 individuals of the EUROBATS and GTEx projects (Online Methods and Supplementary Table 10), we observed evidence of eQTL asso ciations with nearby genes (P < 1 × 10 −6 ) at 21 loci, including 14 with supportive evidence of colocalization of lead phenotypic and eQTL associations (Online Methods and Supplementary Table 10 ).
Experimental validation of putative effector genes in cellular adipogenesis models
We sought to experimentally validate the role of five putative effector genes (IRS1, CCDC92, DNAH10, L3MBTL3 and FAM13A) across four loci that showed associations with (i) expression of nearby transcripts in subcutaneous adipocytes, (ii) lower peripheral adipos ity, and (iii) higher metabolic disease risk ( Supplementary Fig. 11 , Supplementary Tables 10 and 13, and Supplementary Note). We used small interfering RNA (siRNA) to reduce mRNA levels for these five genes in OP9K cells, a mouse adipocyte model that shows rapid differentiation in response to adipogenic stimuli 45 . Knockdown of the Irs1, Ccdc92, Dnah10 and L3mbtl3 genes significantly reduced both the mRNA levels of the target gene (Fig. 4a, top) and lipid accumulation (Fig. 4a, bottom and Fig. 4b) . These results are directionally consistent with the association of the insulinraising alleles at these loci with lower expression of these genes in subcu taneous adipocytes and with lower levels of peripheral fat (Fig. 4c) . Knockdown of Fam13a reduced mRNA levels (Fig. 4a, top) but did not significantly affect preadipocyte lipid accumulation (Fig. 4a, bot  tom and Fig. 4b) . In contrast to the other four genes, the risk allele at FAM13A was associated with higher mRNA expression of this gene in subcutaneous adipocytes (Fig. 4c) .
DISCUSSION
Our data implicate an impaired capacity to adequately expand the peripheral adipose tissue compartments in human insulin resist ance and related disease in the general population. These results substantially augment existing evidence 31,36,46-49 by clarifying the extent and relevance of adipose tissue dysfunction in cardiometa bolic disease and by providing new mechanistic insights into its underpinning biology.
Our results are consistent with the existence of dozens of genomic regions at which common genetic variation affects cardiometabolic disease risk via subtle 'lipodystrophylike' mechanisms. Although these common genetic mechanisms have individually small effects, their cumulative effect is large and relevant to a large fraction of the population. For instance, we observed a difference of ~700 g in leg fat mass between the top and bottom 20% of the population distri bution for risk alleles. We also show a polygenic contribution to an extreme phenotype, referred to as FPLD1 or Köbberlingtype lipo dystrophy, illustrating the contribution of common alleles to severe forms of insulin resistance. At given loci (for example, PIK3R1), we found that genetic variants at the two extremes of the allele frequency spectrum result in corresponding consequences at the extremes of the phenotypic severity spectrum. These findings strongly concur with the notion that molecular and pathophysiological mechanisms first described in severe forms of lipodystrophic insulin resistance are relevant to the general population.
While a centripetal distribution of body fat is a wellrecognized risk factor for metabolic and cardiovascular disease [50] [51] [52] [53] [54] , there is con siderable confusion about the underlying mechanisms and relative importance of lower peripheral fat versus higher central adiposity. Although supportive of a role for central fat accumulation, different lines of evidence from this study suggest a role for impaired periph eral fat deposition in insulinresistant cardiometabolic disease in the general population. This evidence includes strong associations with gluteofemoral adiposity, overlap with regulatory regions in adipose tissue and with genomic loci known to cause lipodystrophies, as well as functional characterization in adipocytes. These findings provide evidence from largescale human genetics studies, which add to a body of research about the links between subcutaneous and lowerbody adi pocyte phenotypes and a favorable metabolic profile 19,55-57 .
By combining populationscale association studies with eQTL data from adipose tissue and experimental evidence from mouse cellular models, we provide evidence that specific risk loci influence adipose gene expression, resulting in impaired adipogenesis, reduced periph eral fat depots and, ultimately, increased risk of cardiometabolic disease. For the L3MBTL3, DNAH10 and CCDC92 genes, evidence presented in this study provides, to our knowledge, the first link with impaired adipocyte differentiation capacity. L3MBTL3 recognizes methylated lysine residues on histone tails 58 , and previous genome wide anthropometric studies have implicated the L3MBTL3 locus in adult height and length at birth [59] [60] [61] . At the chromosome 12q24 locus, our analyses are consistent with the implication of both CCDC92 and DNAH10 in impaired adipogenesis. CCDC92 is a coiledcoil domain protein that interacts with proteins at the centriole-ciliary interface 62 . DNAH10 encodes one of the heavy chains of the dynein arms of motile cilia, and it is therefore surprising that its product seems to have cell autonomous effects on adipocyte biology. However, an essential splice site mutation in DNAH10 has previously been reported to cosegregate with abnormal circulating HDL cholesterol levels in a family 63 , while the locus containing both CCDC92 and DNAH10 has been associated with circulating levels of large HDL particles 64 , further supporting an unexpected role for these proteins in metabolism.
Our results have preventive and therapeutic implications for car diovascular and metabolic disease. First, they suggest that attempts to develop pharmacological agents acting on the molecular mechanisms of obesity are likely to reduce cardiometabolic risk if they reduce calorie intake (for example, by acting on appetite) or reduce ectopic fat deposition in tissues such as the liver, muscle and pancreas, but not if they impair adipogenesis or peripheral fat deposition. Agents that promote adipocyte differentiation and increase peripheral adipose A r t i c l e s mass via action on peroxisome proliferatoractivated receptor γ have powerful antidiabetic actions 65, 66 and in some cases have a beneficial effect on cardiovascular outcomes 67, 68 , although some of these agents have been reported to have an adverse cardiovascular safety profile 69 . An early but vital challenge in the translation of genetic findings into therapeutic insight is the ability to identify likely effector transcripts underlying genetic associations. In the current study, we identify puta tive effectors of genetic associations and the tissues in which they operate. We also demonstrate that these genetic variants often affect risk of type 2 diabetes and coronary disease in a consistent direction, which suggests that targeting these pathways may satisfy current regulatory requirements that antidiabetic agents not be associated with unacceptable cardiovascular risk 70 . This is particularly true of findings from both gain and lossoffunction variants in the LPL gene and risk of type 2 diabetes, which are directionally consistent with those previously reported for the same mutations and risk of heart disease 38 . Notably, the directional concordance for risk of heart disease and type 2 diabetes is in contrast to genetic evidence for other lipidlowering agents (for example, cholesterollowering variants near the molecular target of statins) 71 . In the context of a growing body of evidence linking lipolysis and heart disease risk 38,72-75 , these data suggest that enhancing lipoprotein lipase activity may also become a viable preventive or therapeutic strategy in type 2 diabetes.
In interpreting the results of this study, it is important to note that combining multiple genetic association analyses to gain insights about a latent unmeasured phenotype (insulin resistance) is not immediately comparable with a univariate genomewide association study of a trait (for example, fasting insulin). However, we validated these genetic vari ants as being strongly associated with goldstandard measures of insulin sensitivity, with multiple insulinresistancerelated diseases, including a severe form of insulinresistant partial lipodystrophy, and showed overlap with monogenic insulinresistanceassociated genes. Thus, approaches to leverage additional sources of evidence to prioritize genomic variation (such as multiple phenotypes or putative functional class 76 ) represent a powerful use of extant genetic association results to advance understand ing of biology previously intractable to conventional strategies.
Our results were based on genomewide analyses of fasting insulin adjusted for BMI 28,29 , and we did not identify loci with a primary effect on higher adiposity and secondary association with insulin resistance (for example, FTO). Our approach was more likely to identify loci influ encing insulin resistance at a given level of adiposity. Prompted by the strong association pattern of the genetic scores and variants, we focused on the evaluation of mechanisms linking lower levels of peripheral adi posity with insulin resistance. The importance of adipose function as a prominent driver of common insulin resistance is highlighted by the observation that half of all variants associated with fasting insulin at genomewide significance (without adjustment for BMI) in a previ ous study 28 were included in our genetic score. However, our results do not preclude the presence nor diminish the importance of other mechanisms underlying insulin resistance 5, 77 . Indeed, the associations we observe of the genetic score with central fat, visceral fat and liver enzymes would be further strengthened after adjustment for overall adi posity. While we conclude that our findings implicate a primary effect on impaired adipose function and a secondary effect on insulin resist ance, we cannot entirely exclude the possibility of the reverse, nor the possibility that there are pleiotropic contributions to the associations.
Collectively, our findings support the notion that the limited capac ity of peripheral adipose tissue to store surplus energy is implicated in human insulin resistance and related cardiometabolic disease in the general population. Furthermore, we highlight putative effector genes, tissues and mechanisms underpinning this link. A r t i c l e s 13. Semple, R.K., Savage, D.B., Cochran, E.K., Gorden, P. & O'Rahilly, S. 
ONLINE METHODS
Study design. We integrated the results of genomewide analyses on insulin and lipid phenotypes with the aim of identifying genetic variants associated with an insulin resistance phenotypic pattern (Supplementary Figs. 1-4) . We then investigated the mechanistic links of genetic variation at the 53 genomic regions identified with cardiometabolic diseases by integrating analyses of (i) cardio metabolic traits and outcomes from up to 451,193 individuals; (ii) detailed continuous metabolic traits from 12,848 deeply phenotyped individuals; (iii) genetic and clinical features from 37 individuals diagnosed with FPLD1; (iv) gene expression from over 100 separate eQTL data sets; and (v) siRNA mediated knockdown of putative effector genes in experimental adipogenesis models (Supplementary Figs. 1 and 2, and Supplementary Table 1) .
Participating studies. Lists of phenotypes, participating studies and sample sizes for each analysis are in Supplementary Figures 1 and 2 79 . A total of 3,101 participants with available DEXA data were included in analyses of detailed anthropometry, while 9,150 participants were included in analyses of change in hip or waist circumference in individuals who gained weight during followup.
EPICInterAct is a case cohort study nested within the EPIC study, a cohort study of 519,978 European participants 80 . Over an average of 8 years of follow up, 12,403 individuals who were free from diabetes at baseline were identified as having incident type 2 diabetes 80 . InterAct has also defined a randomly selected subcohort of 16,154 individuals free from diabetes at baseline 80 . Data on 15,357 individuals with available genotyping and not overlapping with DIAGRAM participants 34 were included.
UK Biobank is a populationbased cohort study of ~500,000 people aged between 40-69 years who were recruited in 2006-2010 from several centers across the UK 81 . Associations with prevalent type 2 diabetes were estimated in 111,016 individuals (4,586 cases and 106,430 controls) of the initial UK Biobank data set. We also used the UK Biobank data for anthropometry analyses and for a sensitivity analysis of prevalent coronary heart disease (selfreported myocardial infarction or angina) in 5,369 cases and 106,969 controls.
The UK Household Longitudinal Study (UKHLS; also known as Understanding Society) is a longitudinal panel survey of 40,000 households representative of the population of the UK. Participants were surveyed annually beginning in 2009 and contributed information relating to their socioeconomic circumstances, attitudes and behaviors via a computerassisted interview. For a subset of individuals who took part in a nurse health assess ment, blood samples were taken and genomic DNA was analyzed.
In addition to individuallevel genotyping data, we used genomewide metaanalysis results on a variety of cardiometabolic traits and disease endpoints (Supplementary Figs. 1 and 2, and Supplementary Table 1) .
Detailed anthropometric analyses. In the Fenland and EPICNorfolk studies, body composition was determined by DEXA using a Lunar Prodigy advanced fan beam scanner (GE Healthcare) with enCORE software version 14.10.022 (GE Healthcare). Participants were scanned by trained operators using stand ard imaging and positioning protocols. The coefficient of variation for scan ning precision, calculated from 30 consecutive scans, was 2% for total fat mass. enCORE software was used to demarcate regional boundaries. All images were manually processed by one trained researcher, who corrected demarcations according to a standardized procedure. The boundaries of body regions are described in detail in the Supplementary Note. In the UK Biobank study, body fat percentage was estimated by bioimpedance using the Tanita BC418MA body composition analyzer.
Association of genetic variants with insulin resistance phenotypes. A dys lipidaemic pattern with higher triglyceride levels and lower HDL cholesterol levels is considered to be characteristic of the clinical presentation of insulin resistance 13 and has been used to specifically identify individuals with insulin resistance 30 . In a previous largescale genomewide discovery study of genetic determinants of fasting insulin levels, of the 19 fastinginsulinassociated loci we identified, 10 were strongly associated with higher triglyceride levels and lower HDL cholesterol levels 28 . This pattern of association was used to refine loci, which were then validated as being associated with goldstandard meas ures of insulin resistance 31 . The loci associated with insulinemia but not with lipid traits included TCF7L2 (ref. 28), which has primarily been implicated in insulin secretion rather than resistance 82 . These findings suggested that combined association with this triad of phenotypes could help identify specific genetic determinants of insulin resistance.
With this background, we systematically triangulated the results from the association of ~2.4 million SNPs with fasting insulin adjusted for BMI (from up to 108,557 participants of the MAGIC Consortium) 28,29 and HDL cholesterol and triglycerides (from up to 188,577 participants of the Global Lipids Genetics Consortium) 32 using publicly available genomewide results (Supplementary Figs. 1-4) . For analyses of fasting insulin adjusted for BMI, we used Metabochip association results 28 when available. We aligned alleles across the three phenotypes such that the effect allele was the insu linraising allele. We took forward for further analysis all SNPs associated with higher fasting insulin adjusted for BMI, higher triglycerides and lower HDL cholesterol at P < 0.005 for each of the three traits. The prior probability for association of a given SNP with the three traits and in prespecified direc tional concordance under the null hypothesis corresponds to 0.005 × 0.0025 × 0.0025 = 3.1 × 10 −8 . In each 1Mb locus, we retained the lead SNP for associa tion with fasting insulin levels for further analysis (Supplementary Fig. 4) .
Fasting insulin analyses adjusted for BMI were chosen because we were interested in identifying genetic determinants of insulin resistance for a given level of adiposity. It has been proposed that adjusting genetic association analy ses for covariates such as BMI might result in a bias known as 'collider bias' (refs. 83,84) . Therefore, we assessed the associations of the 53 lead SNPs for a bias in the identification of variants primarily associated with BMI and artifi cially associated with fasting insulin levels, but we found no evidence of such bias (Supplementary Fig. 12 ).
Statistical methods. We studied the association of individual SNPs and of genetic scores with continuous metabolic traits and disease endpoints. Where individuallevel genotype data were available, the associations of genetic vari ants or scores (the sum of the effect alleles) with outcomes were estimated using multivariate linear, logistic or Cox regression models. For resultlevel associa tion data, we used the inversevarianceweighted method developed by Burgess et al. 85 , assigning a weight of 1 to each SNP, to approximate the association of an unweighted genetic risk score. Statistical analyses were conducted using STATA v14.1 (StataCorp), R v3.2.2 (R Foundation for Statistical Computing), and METAL 29 . All P values presented in the study are twotailed P values.
Analyses in a severe form of partial lipodystrophy and insulin resistance. We studied the clinical and genetic characteristics of 37 women with FPLD1 (also called Köbberlingtype familial partial lipodystrophy).
All cases were referred to the insulin resistance/lipodystrophy specialist center (led by R.K.S., D.B.S. and S.O'R. in Cambridge, UK). FPLD1 is currently a clinical diagnosis used to describe predominantly women with selective paucity of limb adipose tissue, central obesity, severe insulin resistance and a higher risk of type 2 diabetes 86, 87 . As some women with lipodystrophy due to lossoffunction mutations in PPARG manifest a similar phenotype (FPLD3), mutations in this gene were excluded for all FPLD1 cases included in this study. The biochemical and anthropometric phenotypes of the 37 patients with FPLD1 were compared with those of female participants of the Fenland study. In these analyses, we compared the phenotypes of the 37 patients with FPLD1 to those of all women in the Fenland study (Fig. 2) and to those of obese women in the Fenland study ( Fig. 2 and Supplementary Table 8) who had a BMI similar to that of the women with FPLD1.
To understand the genetic basis of FPLD1, we carried out exome sequencing analyses in 18 individuals from 9 pedigrees with FPLD1 for which no clear candidate mutations or genes had been identified. Sequencing, variant calling and annotation were performed as described previously (family 2 (ref. 88); families 1 and 3-9 as part of the UK10K project) 89 . Calls were annotated with 1000 Genomes Project allele frequencies and NCBI dbSNP database build 132 (ftp://ftp.ncbi.nih.gov/snp/organisms/human_9606/). Variants were defined as potentially functional if they were nonsynonymous, resulted in loss or gain of a stop codon or a frameshift, or occurred within essential splice sites. Those unlikely to have a functional impact were removed, as were all variants found with a MAF >1% in individuals of European descent from 1000 Genomes Project Phase 1v3 (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/ release/20110521/) or NHLBI ESP Exomes (accessed January 2012; http://evs. gs.washington.edu/EVS/). Further filtering was then implemented to retain only variants in genes seen in multiple patients.
We compared the burden for the 53SNP genetic score in the 37 patients with FPLD1 to that for 5,296 unrelated control women from UKHLS. Genome wide genotyping of UKHLS women was performed using the Illumina Infinium HumanCoreExome12 v1.0 BeadChip. Genotype calling was performed using Illumina GenCall software. Genomewide genotyping of the patients with FPLD1 was performed using the Illumina Infinium CoreExome24v1.0 chip. Before imputation, SNPs were excluded on the basis of quality control cri teria applied in PLINK 90 (version 1.07) if they (i) had a MAF <0.01; (ii) had a Hardy-Weinberg equilibrium P < 1 × 10 −6 ; (iii) had a call rate <99%; (iv) showed differential missingness between cases and controls with P < 1 × 10 −6 ; or (v) showed differential genotyping between the CoreExome24v1.0 and CoreExome12v1.0 chips in a subset of 96 samples genotyped using both chips. Samples were excluded before imputation in PLINK if they (i) had a call rate <95%; (ii) had autosomal heterozygosity >3 s.d. from the mean; (iii) had pi hat >0.05 in calculations of pairwise identity by descent (one individual was removed for each of these pairs, preferentially retaining female samples); (iv) had a proportion of concordance between the genomewide and Fluidigm genotypes at 24 sites <90%; or (v) were ancestry outliers identified on the basis of a principalcomponents analysis. Imputation was performed using the 1000 Genomes Project Phase 3 reference panel with SHAPEIT2 (version 2.r644) 91 and IMPUTE2 (version 2.3.1) 92 . FPLD1 cases and UKHLS controls were imputed together. In an analysis of the genetic principal components derived from genomewide genotyping (defined on the basis of the combined sample), the 37 patients with FPLD1 clustered with the UKHLS control women (Supplementary Fig. 13 ). Association analyses were performed in R by logis tic regression adjusting for age and the first ten genetic principal compo nents. We also derived a permutationbased null comparator by performing 100,000 permutations in which 53 SNPs (>1 Mb apart) were randomly selected from genomewide analyses of FPLD1 status adjusted for age and principal components and performing summary statistic Mendelian randomization 85 . Of 100,000 iterations, 201 had a P value less than our observed association (P permutation = 2.01 × 10 −3 ).
Prioritization of putative effector genes. We sought to determine the putative effector genes at the 53 loci. We combined (i) information on physical proxim ity, (ii) eQTL data from over 100 repositories, (iii) functional and regulatory annotations, and (iv) previous knowledge about causal genes for monogenic forms of insulin resistance.
For physical proximity analysis, we reviewed genes within a 1Mb window centered on each lead SNP and generated regional association plots using LocusZoom 93 . For eQTL analysis, we analyzed both publicly available and unpublished data sets (see below). For functional annotation, we used the gene and tissue/cell type prioritization functions of the integrative software DEPICT 44 , to gain insights about putative effector genes, tissues and cell types. We also looked for nonsynonymous variants in linkage disequilibrium (LD) with the lead SNP (r 2 > 0.8) in Europeanancestry populations using HaploReg (v3) 94 .
We assessed the overlap of the identified loci with chromatin state defini tions of active enhancers and active promoters for 98 cell types from the NIH Epigenomics Roadmap project, including a total of 196 genomic annotations. For each of the 53 lead SNPs, we identified the set of proxy variants in high LD (CEU r 2 > 0.8) using SNAP 95 and defined a 'locus' as a lead SNP plus its proxies. We then calculated the number of loci where at least one variant at the locus overlapped a given annotation. We determined enrichment in overlap at the 53 loci in comparison to an expected distribution built from randomly selected matched loci. First, we identified all variants with genomewide significant association (P < 5 × 10 −8 ) with any trait in Europeans from the GWAS catalog 96 . We then pruned this set of variants (using a CEU r 2 threshold of 0.1), resulting in a list of independent traitassociated variants. For each of these variants, we constructed a background locus as the set of proxy variants in high LD (CEU r 2 < 0.8). For each of the 53 loci, we then selected a locus from the background set matched with respect to the total number of proxy variants, the total genomic distance covered and the distance of the midpoint to the closest gene transcription start site. We then recalculated the overlap of each annotation in the set of matched background loci. We obtained the expected overlap for each annotation by averaging over 1 million permuted background locus sets. We then tested for enrichment of each annotation with a binomial test using the observed number of overlapping loci, total number of loci and expected percentage of overlapping loci.
We compiled a list of 13 genes (PPARG, INSR, PIK3R1, TBC1D4, LMNA, PLIN1, AKT2, CIDEC, AGPAT2, BSCL2, CAV1, PTRF and PCYT1A) known to cause monogenic forms of insulin resistance from the literature 13 and used this to look for overlap with genes in the identified regions. Two experts in the clinical care of patients with monogenic insulin resistance (R.K.S. and D.B.S.) reviewed the curated list.
Analysis of eQTLs in multiple tissues. Using a curated collection of over 100 separate eQTL data sets, we queried whether the 53 lead SNPs or their proxies (r 2 > 0.8) were associated with transcript expression in a wide range of tissues. Proxy SNPs in LD in Europeanancestry populations were identified using SNAP 95 . For this study, we considered all associations below a Pvalue cutoff of 1 × 10 −6 . A general overview of a subgroup of >50 eQTL data sets has been published 97 , with specific citations for the >100 data sets included in the current query provided in the Supplementary Note. Specific analysis of eQTLs in subcutaneous adipose tissue. We analyzed in depth the association of lead SNPs with gene expression in subcutaneous adi pose tissue using two subcutaneous adipose tissue ciseQTL data sets. The first data set was generated by the EUROBATS Consortium and consists of samples from wellphenotyped healthy female twins (n = 766) with eQTLs derived as described previously 98 . We also used the subcutaneous adipose tissue data (n = 298) generated by the GTEx Consortium (version 6) 99 , which were obtained from http://www.gtexportal.org/ on 20 November 2015. GTEx results were limited to GENCODE 'protein_coding' and 'lincRNA' biotype transcripts, and only variants with MAF >0.01 were used. LD statistics between the index SNP (lead SNP for fasting insulin at the locus) and the most signifi cant expression SNP for the gene were calculated in PLINK 1.9 using 1000 Genomes Project Phase 1 version 3 Europeanancestry samples 90 . We also assessed the regulatory trait concordance (RTC) value for SNPs associated with gene expression in adipose tissue, to assess the likelihood of colocalization of signal with the lead eQTL signal in that region 100 . In brief, if the index variant and the eQTL do tag the same causal variant, it is expected that removing the genetic effect of the index variant will have a significant consequence on the eQTL association. To this end, the RTC method assesses the likelihood of a shared functional effect between a GWAS variant and an eQTL by quantify ing the change in the statistical significance of the eQTL when correcting for the genetic effect of the index variant and comparing its correction impact to that of all other SNPs in the interval. We considered an RTC of ≥0.8 or high LD between the lead eQTL SNP and the traitassociated SNP (r 2 > 0.8) to be supporting evidence of colocalization.
Functional studies in mouse OP9-K cells. We sought to experimentally vali date candidate causal genes at loci associated with lower levels of peripheral adiposity, higher risk of type 2 diabetes and gene expression in subcutaneous adipose tissue ( Supplementary Fig. 11 and Supplementary Note). We studied the effects of gene knockdown using siRNA on adipogenic differentiation in mouse OP9K cell lines. The mouse OP9K cell line used in this study is a model suitable for midthroughput screening of genes influencing adipogene sis. OP9K cells are clonal cells derived from mouse stromal OP9 cells obtained from the bone marrow, which accumulate large lipid droplets after 72 h of adi pogenic stimulation 45 . OP9K cells were grown and differentiated using oleic
